Skip to main content
Fig. 8 | BMC Immunology

Fig. 8

From: Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells

Fig. 8

WiDr-injected SCID mice were treated with NaB, NK-92MI, anti-CEA CAR NK-92MI, and anti-CEA CAR NK-92MI + NaB for 15 days. Tumours were measured at Days 0, 4, 9, 12 and 15 after treatment. a Tumour growth curves show that the anti-CEA CAR NK-92MI and anti-CEA CAR NK-92MI + NaB treatments inhibit tumour growth significantly better than the control, NaB alone, or NK-92MI alone. b Treatment with NaB or NK-92MI did not significantly inhibit tumour growth relative to the control. Tumour size was significantly reduced by treatment with anti-CEA CAR NK-92MI and even more so in response to the combination of anti-CEA CAR NK-92MI and NaB

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us